AI in Drug Discovery: Surveying the Breadth of the Challenges

The biotech sector is experiencing a surge in AI investment, with companies committing billions to accelerate drug discovery. While AI and machine learning have shown promise in fields like image recognition and language processing, their application in drug discovery faces significant challenges due to the vast and largely unexplored chemical space—estimated at over 10^60 potential drug-like molecules. AI models rely on training data, but their ability to predict novel, effective compounds remains uncertain, especially for complex diseases where biological mechanisms are poorly understood. AI performs well when tasks align closely with existing data, such as predicting molecular interactions for known structures. However, its effectiveness diminishes when addressing truly novel cases, as seen with tools like AlphaFold, which struggle with unfamiliar biological targets. The core issue lies in target selection—a critical step requiring scientific judgment that AI cannot yet replicate. Even with curated datasets, AI lacks the nuanced decision-making of experienced researchers, who must weigh incomplete data across multiple parameters. The industry’s success with AI will depend on realistic expectations and strategic deployment. Companies must identify specific problems where AI can add value, invest in robust data infrastructure, and maintain scientific rigor. Overhyping AI’s capabilities risks misallocating resources, while thoughtful integration could streamline parts of drug discovery, such as screening vast chemical libraries or optimizing existing compounds. Despite these challenges, AI is already transforming certain aspects of biotech research. Advances in computational power and algorithmic improvements have enhanced pattern recognition, but the field remains constrained by gaps in biological knowledge. For now, AI should complement—not replace—human expertise, particularly in areas where scientific judgment and adaptability are essential.